|
The Council on Radionuclides and Radiopharmaceuticals (CORAR) is an association comprised of
companies in the United States and Canada who manufacture and distribute radiopharmaceuticals, sealed sources, and radionuclides primarily used in medicine and
life science research. CORAR is tasked with advocating for regulations and legislation that facilitate the growth and viability of its member
companies. Specifically, CORAR focuses on manufacturing, transportation, safety, security, reimbursement, and regulatory issues that can impact the
radiopharmaceutical and radionuclide industry. CORAR must pursue a proactive agenda which includes education of the Congress and regulatory bodies on the
benefits of radiopharmaceuticals and radionuclides to medical and life sciences.
Activities of CORAR include:
- To monitor and participate in the legislative and regulatory process at the federal, state,
local and international levels to ensure the appropriate treatment of radiopharmaceuticals and radionuclides, and radioactive products used in life medical
sciences.
- To maintain effective contact with regulatory and legislative staff to supply timely information
to assist regulatory agencies and legislative bodies who are in the process of developing new or revised regulations, regulatory guidelines and legislation;
- To encourage a policy of appropriate and adequate reimbursement for costs of using
radiopharmaceuticals under Medicare and other systems for health care coverage;
- To develop and encourage the use of industrial standards to assure safe, reliable and high
quality products and services;
- To educate Congress, federal regulatory agencies, medical specialty societies, the public, and
other medical trade groups on the benefits of radiopharmaceuticals;
- To develop and maintain an interactive association with medical, industrial, professional, and
academic associations who share common concerns for the effective and safe utilization of radiopharmaceuticals and other radioactive products;
- To provide a forum for interests of the radionuclide and radiopharmaceutical industries.
|
